Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318051 · ClinicalTrials.gov registry record
Sample Collection for Ongoing Research and Product Evaluation Study
A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Natera.
- Recruiting
- Registry status
- 9,600
- Enrollment target
- 1
- Study location
NCT07318051: Recruiting study of Breast Cancer and Prostate Cancer, sponsored by Natera.
NCT07318051 is a study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Natera. The registered enrollment target is 9,600 participants, above the 2,795-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (243% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318051, a study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Natera.
- RECRUITING
- Registry status
- 9,600 participants
- Enrollment target
- 1
- Study location
Study Summary
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
Primary Outcome
To collect de-identified whole blood and residual tissue specimens for research use and the development of blood-based cancer monitoring and detection assays.
Conditions Studied
Study Locations (1)
Texas
- Natera, Inc. - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,600 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2035-01 |
What NCT07318051 shows while recruiting
NCT07318051 is an observational study that tracks outcomes without assigning an intervention. Its 9,600 participants enrollment target places it among the larger protocols in the corpus, above the 2,795-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (243% higher).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07318051 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07318051 about?
NCT07318051 is a clinical study titled "Sample Collection for Ongoing Research and Product Evaluation Study". The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's mo...
What is the current status of trial NCT07318051?
This trial is currently recruiting. The enrollment target is 9,600 participants. The study started on 2025-07-21. Estimated completion is 2035-01.
What conditions does trial NCT07318051 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer.
Who is sponsoring clinical trial NCT07318051?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07318051 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07318051's enrollment target sits among peer trials
9,600 18th of 1224 higher than 1,207 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI